Virpax Pharmaceuticals Inc.
13F holders, Q3 2024 (September 30)9holders +2
3new positions
1sold out
1famous investor
$0.69avg. 13F price*
At the end of Q3 2024, 9 institutions reported holding Virpax Pharmaceuticals Inc. in their 13F filings, up 2 from Q2 2024. 3 opened new positions and 1 sold out. The largest holders were Citadel Advisors ($22K), Geode Capital Management, LLC ($19K) and UBS Group AG ($14K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Virpax Pharmaceuticals Inc.
- CUSIP
- 928251206
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $50K |
| Exits | 1 | $10K |
All 13F filers, Q2 2024 → Q3 2024: 91,944 shares bought and 20,000 shares sold, net +71,944 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Citadel Advisors | 0.00% | New | 31,382 | $22K |
| Geode Capital Management, LLC | 0.00% | New | 27,971 | $19K |
| UBS Group AG | 0.00% | Add +1779.9% | 20,435 | $14K |
| Two Sigma Securities, LLC | 0.00% | New | 12,522 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +22.0% | 3,837 | $3K |
| Signature Resources Capital Management, LLC | 0.00% | No change | 50 | $35 |
| Bank of America Corp. | 0.00% | Add +428.6% | 37 | $26 |
| Morgan Stanley | 0.00% | No change | 15 | $10 |
| Hantz Financial Services, Inc. | 0.00% | No change | 10 | $0 |
"% of holder's portfolio" is VIRPAX PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Virpax Pharmaceuticals Inc. the manager owns.